Those are cut and pastes from Quarterly and Annual filings.
They are statements about the total cost of the Phase 3 trial and the estimated costs yet to be incurred.
Nothing extremely noteworthy.
No, the Form 4s are a different matter.
Those are noteworthy in that the Chief Medical Officer received significant options. He is the brains behind Multikine. I believe he will be asked to sign on with the BO pharma, if and when that occurs.
Market Data 
Markets 
AI
